Stocknear Logo Stocknear
/
Popular
Login

Mirum Pharmaceuticals Inc...

39.11
0.36 (0.93%)
At close: Apr 17, 2025, 3:59 PM
39.05
-0.15%
After-hours: Apr 17, 2025, 04:32 PM EDT
0.93%
Bid 37.21
Market Cap 1.92B
Revenue (ttm) 336.89M
Net Income (ttm) -87.94M
EPS (ttm) -1.85
PE Ratio (ttm) -21.14
Forward PE -122.22
Analyst Buy
Ask 40.69
Volume 269,719
Avg. Volume (20D) 523,431
Open 39.21
Previous Close 38.75
Day's Range 38.35 - 39.44
52-Week Range 23.14 - 54.23
Beta 1.01

About MIRM

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment o...

[Read more]
Industry Biotechnology
Sector Healthcare
IPO Date Jul 18, 2019
Employees 322
Stock Exchange NASDAQ
Ticker Symbol MIRM
Website https://www.mirumpharma.com
Full Company Profile

Analyst Forecast

According to 11 analyst ratings, the average rating for MIRM stock is "Buy." The 12-month stock price forecast is $66, which is an increase of 68.75% from the latest price.

Stock Forecasts

Next Earnings Release

Mirum Pharmaceuticals Inc. is scheduled to release its earnings on May 7, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
1 month ago
-7.01%
Mirum Pharmaceuticals shares are trading lower aft... Unlock content with Pro Subscription
10 months ago
+27.31%
Mirum Pharmaceuticals shares are trading higher after the company announced interim results from two Phase 2b studies evaluating volixibat in patients with primary biliary cholangitis and primary sclerosing cholangitis.
news image

4 days ago · businesswire.com

Mirum's LIVMARLI Now FDA Approved in Tablet Formulation

FOSTER CITY, Calif.--(BUSINESS WIRE)---- $MIRM #alagillesyndrome--Mirum's LIVMARLI Now FDA Approved in Tablet Formulation.

news image

1 week ago · businesswire.com

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).

news image

3 weeks ago · businesswire.com

LIVMARLI Now Approved in Japan for ALGS and PFIC

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #alagillesyndrome--LIVMARLI Now Approved in Japan for ALGS and PFIC.

news image

3 weeks ago · seekingalpha.com

Mirum Pharmaceuticals: Set Fair For Share Price Momentum - Reversing My Sell Call

Mirum Pharmaceuticals, Inc. stock has risen nearly 25% since my "Sell" rating in October, prompting a re-evaluation of the company's performance and prospects. Mirum markets three drugs: LIVMARLI, Cho...

news image

4 weeks ago · zacks.com

Mirum's Heavy Dependence on Livmarli for Revenues Remains a Woe

MIRM's high reliance on lead drug, Livmarli for revenues remains a worry. Failure to generate sufficient revenues from Livmarli sales is likely to hurt the stock.

news image

1 month ago · zacks.com

MIRM's Q4 Loss Wider Than Expected, Revenues Beat Estimates

Mirum's fourth-quarter 2024 earnings miss estimates while revenues beat the same.

news image

1 month ago · seekingalpha.com

Mirum Pharmaceuticals, Inc. (MIRM) Q4 2024 Earnings Call Transcript

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Andrew McKibben - Senior Vice President, Strategic Finance & Investor Rela...

news image

1 month ago · zacks.com

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates

Mirum Pharmaceuticals, Inc. (MIRM) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.66 per share a year ago.

news image

1 month ago · businesswire.com

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for the fourth quarter and year-end 2024 and provided a business update. “2024 was ano...

news image

1 month ago · zacks.com

Wall Street Analysts Predict a 26.18% Upside in Mirum Pharmaceuticals (MIRM): Here's What You Should Know

The mean of analysts' price targets for Mirum Pharmaceuticals (MIRM) points to a 26.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement ...

Create Price Alert on MIRM

Your price alert will notify you when the stock price is above 39.11.

Add to Watchlist